

Newsletter

Message from the Chief Investigator and Co-lead

Dear VICI Investigators,

Thank you for your efforts which meant that the study not only has fully recruited but also over recruited! It is really exciting to get to this stage in what we hope will be a land mark study for central serous chorioretinopathy. Now our challenge is to keep all patients in the study until the end. Please do everything to ensure patients do so. Thanks again for all your hard work.





With very best wishes,

Prof. Andrew Lotery and Prof. Sobha Sivaprasad

Final recruitment figures

riliai recraitillellit jigares			
VICI sites	Months recruiting	Randomised	% of target*
Southampton	13	8	114
Moorfields	13	19	271
Manchester	13	7	100
Blackburn	12	1	15
Torbay	12	5	77
Leeds	12	8	123
York	12	1	17
Bradford	12	4	67
Sheffield	11	2	33
Sunderland	11	3	50
Brighton	11	5	91
Liverpool	11	2	36
Newcastle	10	7	127
Bristol	10	6	109
Belfast	10	6	120
Frimley Park	9	5	100
Southend	8	6	150
St. Thomas'	7	1	25
King's College	7	1	25
Rugby	7	6	150
Oxford	7	6	171
Wolverhampton	3	5	250
Overall	221	114	104

Study Progress

Screened n=382

Randomised n=114

> Week 1 n=114

Week 4 n=114

3 Months n=92

6 Months n=72

9 Months n=35

12 Months n=15

Table 1. Recruitment data up to 28/02/2018 *Target = recruiting 0.5 patients/month.









VICI Investigators' Meeting 2018

The 3rd VICI investigators meeting was held in Birmingham on 8th March. A big thank-you to everyone who attended and to our invited speakers Sobha Sivaprasad, Clare Bailey, Savita Madhusudhan and Rebecca Kaye. The main discussion points were:

- Retention of participants—it is very important to ensure all participants continue with followup to 12 months and that adherence to the IMP is monitored and recorded.
- Data completeness was really high. Please keep working hard to maintain this; enter any missing data and upload outstanding images to CARF.
- **OCT-A**—CARF have developed protocols for Optovue equipment which were circulated on 6th April 2018. Please pass them on to your photographers.
- OCT-A—an amendment has been submitted to allow capture of OCT-A images at a later time point if it was missed at baseline. Sites will be updated on the progress of the amendment.
- **Analysis of retinal images**—pilot grading of the baseline images is underway. <u>CARF have asked</u> that the EDI covers the correct area of the choroid (i.e. less vitreous, more choroid)—please contact CARF if more details are required (carf@qub.ac.uk).
- Future research Rebecca Kaye provided an insight into her research in Prof Lotery's laboratory investigating the effects of corticosteroids on gene expression in choroidal cells, exciting stuff!

Congratulations to our prize winners!

The following sites were awarded prizes at the Investigators meeting

Highest number of participants recruited

Moorfields

Highest percentage of eligible patients consented to the study

🜟 Liverpool 🌟 Brighton

Highest proportion of images submitted to CARF

🐈 Guy's & St Thomas 🌟 Wolverhampton 🐈 Leeds

Lowest frequency of outstanding data queries

Bristol Eye Hospital 🐈 Southampton 🤺 King's College 🐈 Sunderland 🤺

Bradford

Contact details

Chief Investigator: A.J.Lotery@soton.ac.uk

VICI trial management team:

Email: vici-trial@bristol.ac.uk

Tel: 0117 3422987 Fax: 0117 342 3288 This project is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership.

The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NHS, NIHR or the Department of Health.

*The EME Programme is funded by the MRC and NIHR, with contributions from the CSO in Scotland and NISCHR in Wales and the HSC R&D Division, Public Health Agency in Northern Ireland.